JPRN-UMIN000010435
Recruiting
Phase 2
A clinical phase-II trial of neoadjuvant chemoradiotherapy with S-1 and Gemcitabine for locally advanced pancreatic cancer (PerSeUS-GP02) - PerSeUS-GP02
PerSeUS: Perpetual Study estimated-by United Sections in gifu0 sites40 target enrollmentApril 6, 2013
Conditionsocally advanced pancreatic cancer
Overview
- Phase
- Phase 2
- Intervention
- Not specified
- Conditions
- ocally advanced pancreatic cancer
- Sponsor
- PerSeUS: Perpetual Study estimated-by United Sections in gifu
- Enrollment
- 40
- Status
- Recruiting
- Last Updated
- 2 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- Not provided
Exclusion Criteria
- •1\. Lung fibrosis or interstitial pneumonia. (should be confirmed by chest radiograph or CT within 28 days before the entry) 2\. Watery diarrhea or chronic diarrhea 3\. Regular use of Fenitoin, Warfarin or Frucitocin 4\. Pleural effusion or ascites 5\. Active infection 6\. Other malignancies 7\. Active gastroduodenal ulcer 8\. Serious comorbid illness (heart failure, renal failure, liver failure, intestinal paralysis, uncontrolled diabetes, etc) 9\. Serious mental disorder 10\. Serious drug allergy 11\. Pregnancy, breast feeding, or women who desire to preserve fecundity. Men who want his partner to be pregnant. 12\. Patients who were judged inappropriate for the entry to this study by the investigators
Outcomes
Primary Outcomes
Not specified
Similar Trials
Completed
Phase 2
A clinical phase-II trial of neoadjuvant chemoradiation therapy using S-1 for locally advanced pancreatic cancer (PerSeUS-GP-01)ocally advanced pancreatic cancerJPRN-UMIN000002176PerSeUS-GP40
Recruiting
Not Applicable
A phase II clinical trial of neoadjuvant chemoradiation therapy for pancreatic ductal adenocarcinomapancreatic cancerJPRN-UMIN000035232Department of Gastroenterological Surgery, Faculty of Medicine, Kagawa University50
Not yet recruiting
Phase 1
A phase II clinical trial of neoadjyvant chemoradiation therapy using Gemcitabine combined with IMRT for borderline resectable pancreatic cancerborderline resectable pancreatic cancerJPRN-UMIN000010113Hepato-pamcreato-biliary Surgery and Transplantation, Graduate School of Medicine and Faculty of Medicine KyotoUniversity37
Not yet recruiting
Not Applicable
Phase 2 clinical study of neoadjuvant chemotherapy for HER2-negative primary breast cancer patients using dose dense nab-paclitaxel followed by dose dense Epirubicin and cyclophosphamideHER2 negative primary breast cancerJPRN-UMIN000019787Dept of breast oncology50
Active, not recruiting
Not Applicable
Phase I/II-Studie zur neoadjuvanten Chemotherapie mit nicht-pegyliertem liposomalem Doxorubicin, Paclitaxel und Lapatinib bei Patientinnen mit HER2-überexprimierenden, primärem MammakarzinomeEUCTR2007-000924-42-DESana Klinikum Lichtenberg